Perspective Initiates Early-Stage Study Of FAP-α Targeted Radiopharmaceutical In Cancer Patients

Perspective Therapeutics is a radiopharmaceutical firm developing cutting-edge therapies for cancers all over the body. The company has treated the first patient in its Phase 1/2a clinical trial evaluating [212Pb]PSV359, a targeted alpha therapy for solid tumours expressing fibroblast activation protein alpha (FAP-α). The study aims to determine this radiopharmaceutical's safety and early efficacy, marking a milestone in the development of novel cancer treatments. Patient eligibility for treatment is determined using [203Pb]PSV359 with SPECT imaging, enabling precise tumour targeting.

Markus Puhlmann, Chief Medical Officer of Perspective, said, "We are excited to explore a new avenue to treat cancers expressing FAP-α with [212Pb]PSV359. FAP-α is expressed directly on certain tumors and cells forming the stroma, a part of the tumor microenvironment, which also plays a role in disease progression and treatment outcome in additional solid tumors. This study aims to select a dose for [212Pb]PSV359 to advance as either a monotherapy or eventually in combination with other agents for future clinical development."

"PSV359 showcases the capabilities of our discovery team in creating novel radiopharmaceuticals to provide innovative therapies for cancer patients in need of new treatment options. There has been an extensive development history of FAP-α directed cancer diagnostics and therapeutics. When we selected PSV359 to advance into the clinic, we optimized the construct for preferential uptake and retention in the tumor, in addition to binding affinity to FAP-α and fast clearance from healthy tissues. We look forward to seeing how these characteristics translate into the clinic, and applying these design principles to future constructs to advance into clinical development," said Thijs Spoor, Chief Executive Officer of Perspective.